Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
AUROBINDO PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-23 |
TEVA PHARMA Dec-13 |
AUROBINDO PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 715 | 3,486 | - | |
Low | Rs | 397 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 424.2 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 32.9 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 54.1 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 3.00 | 109.40 | - | |
Avg Dividend yield | % | 0.5 | 3.4 | 16.1% | |
Book value per share (Unadj.) | Rs | 458.1 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 585.94 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 1.6 | 80.5% | |
Avg P/E ratio | x | 16.9 | 26.1 | 64.8% | |
P/CF ratio (eoy) | x | 10.3 | 11.4 | 90.4% | |
Price / Book Value ratio | x | 1.2 | 1.5 | 82.8% | |
Dividend payout | % | 9.1 | 87.5 | 10.4% | |
Avg Mkt Cap | Rs m | 325,753 | 2,761,843 | 11.8% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 35,223 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 248,554 | 1,696,422 | 14.7% | |
Other income | Rs m | 2,906 | 0 | - | |
Total revenues | Rs m | 251,460 | 1,696,422 | 14.8% | |
Gross profit | Rs m | 37,070 | 464,566 | 8.0% | |
Depreciation | Rs m | 12,446 | 137,123 | 9.1% | |
Interest | Rs m | 1,405 | 33,320 | 4.2% | |
Profit before tax | Rs m | 26,125 | 294,122 | 8.9% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 6,849 | -3,591 | -190.7% | |
Profit after tax | Rs m | 19,277 | 105,974 | 18.2% | |
Gross profit margin | % | 14.9 | 27.4 | 54.5% | |
Effective tax rate | % | 26.2 | -1.2 | -2,147.1% | |
Net profit margin | % | 7.8 | 6.2 | 124.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 214,599 | 1,145,757 | 18.7% | |
Current liabilities | Rs m | 114,938 | 999,197 | 11.5% | |
Net working cap to sales | % | 40.1 | 8.6 | 464.1% | |
Current ratio | x | 1.9 | 1.1 | 162.8% | |
Inventory Days | Days | 21 | 91 | 22.7% | |
Debtors Days | Days | 66 | 96 | 68.4% | |
Net fixed assets | Rs m | 176,668 | 554,089 | 31.9% | |
Share capital | Rs m | 586 | 4,176 | 14.0% | |
Net worth | Rs m | 268,399 | 1,884,403 | 14.2% | |
Long term debt | Rs m | 6,190 | 867,418 | 0.7% | |
Total assets | Rs m | 392,125 | 3,876,868 | 10.1% | |
Interest coverage | x | 19.6 | 9.8 | 199.4% | |
Debt to equity ratio | x | 0 | 0.5 | 5.0% | |
Sales to assets ratio | x | 0.6 | 0.4 | 144.9% | |
Return on assets | % | 5.3 | 3.6 | 146.8% | |
Return on equity | % | 7.2 | 5.6 | 127.7% | |
Return on capital | % | 10.0 | 4.9 | 203.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 23,868 | 270,322 | 8.8% | |
From Investments | Rs m | -39,778 | -95,786 | 41.5% | |
From Financial Activity | Rs m | 18,144 | -324,269 | -5.6% | |
Net Cashflow | Rs m | 2,298 | -149,733 | -1.5% |
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare AUROBINDO PHARMA With: ORCHID PHARMA JFL LIFE SCIENCES LTD. DENIS CHEM LAB LYKA LABS SAKAR HEALTHCARE
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.